Last Updated:
10 Mar 2026, 03:29:58 PM (IST)
Lincoln Pharmaceuticals Limited
NSE: LINCOLN BSE: LINCOLN
NSE
629.60
13.00 (2.11%)
Prev Close
616.6
Open Price
617.2
Volume
81,276
Today Low / High
617.2 / 651.45
52 WK Low / High
440 / 677
Range
598 - 661
BSE
631.25
15.70 (2.55%)
Prev Close
615.55
Open Price
619.2
Volume
1,733
Today Low / High
619.2 / 650
52 WK Low / High
439.95 / 679.45
Range
600 - 663
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 629.6 (target range: 598 - 661), reflecting a change of 13 (2.10834%). On the BSE, it is listed at 631.25 (target range: 600 - 663), showing a change of 15.7 (2.55056%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
Lincoln Pharmaceuticals Limited Graph
Lincoln Pharmaceuticals Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Lincoln Pharmaceuticals Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 629.60, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 631.25 | 637.56 | 573.81 - 701.32 |
| 643.88 | 515.10 - 772.65 | ||
| 650.19 | 455.13 - 845.24 | ||
| Bearish Scenario | 631.25 | 624.94 | 562.44 - 687.43 |
| 618.63 | 494.90 - 742.35 | ||
| 612.31 | 428.62 - 796.01 |
Overview of Lincoln Pharmaceuticals Limited
ISIN
INE405C01035
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
56,756
Market Cap
12,639,759,854
Last Dividend
1.8
Official Website
IPO Date
2015-12-17
DCF Diff
-528.12
DCF
1,154
Financial Ratios Every Investor Needs
Stock Dividend of LINCOLN
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-09-12 | September 12, 25 | 1.8 | 1.8 | 2025-09-12 | 2025-10-30 | |
| 2024-09-13 | September 13, 24 | 1.8 | 1.8 | 2024-09-13 | 2024-10-30 | |
| 2023-09-15 | September 15, 23 | 1.5 | 1.5 | 2023-09-15 | 2023-10-30 | |
| 2022-09-15 | September 15, 22 | 1.5 | 1.5 | 2022-09-16 | 2022-10-30 | |
| 2021-09-16 | September 16, 21 | 1.5 | 1.5 | 2021-09-17 | 2021-10-30 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 623.23 Cr | 291.32 Cr | 331.91 Cr | 0.5326 | 10.60 Cr | 113.05 Cr | 88.59 Cr | 82.35 Cr | 41.11 | 123.97 Cr | 0.1321 |
| 2024-03-31 | 580.55 Cr | 283.08 Cr | 297.47 Cr | 0.5124 | 0.00 Cr | 103.14 Cr | 83.22 Cr | 93.30 Cr | 46.58 | 134.33 Cr | 0.1607 |
| 2023-03-31 | 504.95 Cr | 245.75 Cr | 259.21 Cr | 0.5133 | 0.00 Cr | 19.91 Cr | 77.99 Cr | 72.90 Cr | 36.40 | 111.68 Cr | 0.1444 |
| 2022-03-31 | 468.20 Cr | 221.93 Cr | 246.27 Cr | 0.5260 | 0.00 Cr | 18.63 Cr | 164.99 Cr | 69.36 Cr | 34.63 | 105.48 Cr | 0.1481 |
| 2021-03-31 | 414.75 Cr | 201.42 Cr | 213.33 Cr | 0.5144 | 9.36 Cr | 14.52 Cr | 72.02 Cr | 62.25 Cr | 31.08 | 92.84 Cr | 0.1501 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 13.41 Cr | 797.01 Cr | 125.34 Cr | 671.6686 Cr | 0.00 Cr | -13.41 Cr | 78.68 Cr | 186.00 Cr | 0.00 Cr | 0.00 Cr | 107.06 Cr | 106.2158 Cr |
| 2024-03-31 | 5.75 Cr | 700.29 Cr | 107.45 Cr | 592.8359 Cr | 1.07 Cr | -4.68 Cr | 77.17 Cr | 182.48 Cr | 1.32 Cr | 0.00 Cr | 75.15 Cr | 92.2771 Cr |
| 2023-03-31 | 5.05 Cr | 587.42 Cr | 84.95 Cr | 502.4744 Cr | 2.00 Cr | -3.05 Cr | 70.03 Cr | 158.48 Cr | 0.82 Cr | 4.72 Cr | 60.61 Cr | 72.1452 Cr |
| 2022-03-31 | 6.93 Cr | 534.36 Cr | 101.48 Cr | 432.8774 Cr | 2.04 Cr | -4.89 Cr | 72.74 Cr | 150.63 Cr | 0.12 Cr | 4.54 Cr | 29.41 Cr | 90.4862 Cr |
| 2021-03-31 | 11.44 Cr | 452.36 Cr | 85.97 Cr | 366.3923 Cr | 0.52 Cr | -10.92 Cr | 46.61 Cr | 114.49 Cr | 3.54 Cr | 4.29 Cr | 26.32 Cr | 75.8403 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 93.0155 Cr | -78.9474 Cr | -6.4015 Cr | 73.7713 Cr | 7.6666 Cr | 13.4138 Cr | -19.0292 Cr | 109.1886 Cr | -0.9973 Cr | -3.6054 Cr | -1.5092 Cr |
| 2024-03-31 | 63.2172 Cr | -57.3416 Cr | -5.1804 Cr | 23.7407 Cr | 0.6952 Cr | 5.7472 Cr | -39.4759 Cr | 93.3049 Cr | -0.9019 Cr | -3.0045 Cr | -7.1402 Cr |
| 2023-03-31 | 39.2619 Cr | -36.6428 Cr | -4.5013 Cr | 24.9799 Cr | -1.8820 Cr | 5.0520 Cr | -14.2588 Cr | 100.4798 Cr | -0.1444 Cr | -3.0045 Cr | 2.7141 Cr |
| 2022-03-31 | 76.1319 Cr | -78.0802 Cr | -2.5561 Cr | 30.6067 Cr | -4.5044 Cr | 6.9340 Cr | -45.5252 Cr | 95.9393 Cr | 1.4803 Cr | -3.0000 Cr | -26.1292 Cr |
| 2021-03-31 | 69.2695 Cr | -64.2273 Cr | -5.7453 Cr | 60.5192 Cr | -0.7031 Cr | 11.4384 Cr | -8.7503 Cr | 83.7205 Cr | -4.5543 Cr | 0.0000 Cr | 0.7835 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 166.32 Cr | 110.30 Cr | 56.02 Cr | 0.3368 | 19.88 Cr | 28.60 Cr | 14.28 | 23.60 Cr | 0.1720 |
| 2025-09-30 | 163.36 Cr | 110.72 Cr | 52.64 Cr | 0.3222 | 21.81 Cr | 19.98 Cr | 9.98 | 32.66 Cr | 0.1223 |
| 2025-06-30 | 154.07 Cr | 69.38 Cr | 84.68 Cr | 0.5496 | 20.33 Cr | 27.68 Cr | 13.82 | 39.08 Cr | 0.1796 |
| 2025-03-31 | 168.18 Cr | 80.15 Cr | 88.03 Cr | 0.5234 | 23.49 Cr | 11.58 Cr | 5.78 | 19.84 Cr | 0.0688 |
| 2024-12-31 | 146.55 Cr | 68.64 Cr | 77.92 Cr | 0.5317 | 20.44 Cr | 20.77 Cr | 10.37 | 32.63 Cr | 0.1417 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 22.99 Cr | 208.92 Cr | 231.91 Cr | 212.13 Cr | 80.82 Cr | 545.78 Cr | 187.28 Cr | 854.51 Cr | 138.74 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 196.15 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -671.67 Cr |
| 2025-03-31 | 13.41 Cr | 182.58 Cr | 195.71 Cr | 201.69 Cr | 78.68 Cr | 499.94 Cr | 186.00 Cr | 797.01 Cr | 125.34 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 197.41 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -639.26 Cr |
| 2024-09-30 | 32.91 Cr | 164.50 Cr | 197.41 Cr | 224.64 Cr | 84.77 Cr | 523.13 Cr | 183.39 Cr | 779.79 Cr | 140.53 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 27.68 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 11.58 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 20.77 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 26.33 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 23.67 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,812.80 | ₹4,349,514,433,616.00 | ₹3,298,187.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,372.00 | ₹1,691,565,791,760.00 | ₹298,134.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,427.80 | ₹1,498,568,719,232.00 | ₹373,853.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,314.60 | ₹1,094,510,791,983.00 | ₹2,328,593.00 |
| Lupin Limited | LUPIN | ₹2,337.40 | ₹1,068,292,308,200.00 | ₹1,118,737.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹923.10 | ₹928,854,596,169.00 | ₹548,985.00 |
| Mankind Pharma Limited | MANKIND | ₹2,237.70 | ₹923,733,909,614.00 | ₹1,043,890.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,285.90 | ₹746,852,807,016.00 | ₹2,197,557.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,616.50 | ₹671,536,822,500.00 | ₹127,559.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,225.80 | ₹628,122,560,672.00 | ₹1,554,299.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,038.00 | ₹560,371,132,116.00 | ₹1,367,251.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,491.20 | ₹378,323,729,882.00 | ₹56,999.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,999.90 | ₹374,794,378,438.00 | ₹123,025.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹2,117.40 | ₹339,967,004,084.00 | ₹706,890.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,567.80 | ₹297,211,828,212.00 | ₹871,597.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,815.50 | ₹220,387,500,000.00 | ₹3,477.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,327.40 | ₹215,692,105,131.00 | ₹576,727.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹1,039.20 | ₹186,130,976,904.00 | ₹2,029,982.00 |
| Eris Lifesciences Limited | ERIS | ₹1,351.10 | ₹184,042,641,430.00 | ₹100,690.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹12,597.00 | ₹161,618,111,733.00 | ₹24,766.00 |
| Granules India Limited | GRANULES | ₹581.30 | ₹141,063,489,700.00 | ₹712,670.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹712.35 | ₹140,021,741,381.00 | ₹50,451.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹812.35 | ₹128,651,664,788.00 | ₹293,109.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,684.10 | ₹128,011,297,234.00 | ₹43,345.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹940.65 | ₹115,451,618,400.00 | ₹42,515.00 |
| Cohance Lifesciences Limited | COHANCE | ₹295.60 | ₹113,086,846,584.00 | ₹907,550.00 |
| Viyash Scientific Limited | VIYASH | ₹197.45 | ₹86,151,137,188.00 | ₹1,162,070.00 |
| Procter & Gamble Health Limited | PGHL | ₹4,892.10 | ₹81,205,836,682.00 | ₹11,986.00 |
| Strides Pharma Science Limited | STAR | ₹872.90 | ₹80,457,562,051.00 | ₹160,822.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹500.60 | ₹76,642,890,235.00 | ₹265,090.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹338.65 | ₹66,233,781,988.00 | ₹758,443.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹686.70 | ₹62,254,676,925.00 | ₹118,363.00 |
| FDC Limited | FDC | ₹378.05 | ₹61,550,352,256.00 | ₹52,686.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹124.37 | ₹40,360,749,900.00 | ₹1,617,219.00 |
| Innova Captab Limited | INNOVACAP | ₹703.35 | ₹40,249,153,812.00 | ₹21,279.00 |
| Suven Life Sciences Limited | SUVEN | ₹144.43 | ₹33,500,801,218.00 | ₹421,279.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹301.45 | ₹32,847,579,134.00 | ₹64,137.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹353.45 | ₹32,259,381,500.00 | ₹243,536.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,908.60 | ₹31,566,364,029.00 | ₹7,443.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹289.65 | ₹29,046,827,863.00 | ₹71,884.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹509.55 | ₹25,843,919,953.00 | ₹191,509.00 |
Key Executives
Group Marketing Manager
Amit Dwivedi B-PHARM
Gender: male
Year Born: 1976
Whole Time Director
Ashish Rajnikant Patel
Gender: male
Year Born: 1981
Whole Time Director
Hashmukhbhai Ishwarlal Patel
Gender: male
Year Born: 1958
Whole Time Director
Munjal Mahendrabhai Patel
Gender: male
Year Born: 1982
Chief Financial Officer
Darshit Ashvinkumar Shah
Gender: male
Year Born:
Vice President of Technical
Laxmikant Harsola
Gender: male
Year Born:
MD & Whole Time Director
Mahendrabhai Gulabdas Patel
Gender: male
Year Born: 1954
Senior Manager of Operation
Sanjay Bhatt
Gender: male
Year Born:
Senior Manager of Planning & Administration
Sanjiv Patel
Gender: male
Year Born:
Company Secretary & Compliance Officer
Trusha Shah
Gender: female
Year Born:
FAQs about Lincoln Pharmaceuticals Limited
Who is the CEO of the company?
The CEO is Mahendrabhai Gulabdas Patel.
What is the current market price of the stock?
The current price is ₹631.05.
What is the 52-week price range?
The range is ₹440-677.
What is the market capitalization of the company?
The market capitalization is ₹1,263.98 crores.
What is the dividend yield?
The dividend yield is 0.29%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 14.39.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Lincoln Pharmaceuticals Limited (ISIN: INE405C01035) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹1,263.98 crores and an average daily volume of 56,756 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹1.8.